Search research articles
Contact Us
Filters
Showing results (121-130 of 139) with videos related to
Page
of 14
Sort By:
Nature Medicine
|
October 30, 2023
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J S Deutsch, R A Scolyer, E Burton, et al.
ACS Chemical Biology
|
February 28, 2018
Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment
Michel Weïwer, Qihong Xu, Jennifer P Gale, et al.
Journal for Immunotherapy of Cancer
|
October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Samuel Rosner, Sydney Connor, Khaled Sanber, et al.
Trends in Neurosciences
|
April 26, 2018
Progress in Understanding and Treating SCN2A-Mediated Disorders
Stephan J Sanders, Arthur J Campbell, Jeffrey R Cottrell, et al.
Journal for Immunotherapy of Cancer
|
September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Joshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
The New England Journal of Medicine
|
April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 139) with videos related to
Sort By:
Page
of 14
Nature Medicine
|
October 30, 2023
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 30, 2025
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J S Deutsch, R A Scolyer, E Burton, et al.
ACS Chemical Biology
|
February 28, 2018
Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment
Michel Weïwer, Qihong Xu, Jennifer P Gale, et al.
Journal for Immunotherapy of Cancer
|
October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Samuel Rosner, Sydney Connor, Khaled Sanber, et al.
Trends in Neurosciences
|
April 26, 2018
Progress in Understanding and Treating SCN2A-Mediated Disorders
Stephan J Sanders, Arthur J Campbell, Jeffrey R Cottrell, et al.
Journal for Immunotherapy of Cancer
|
September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Joshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
The New England Journal of Medicine
|
April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Page
of 14